Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Receivables (2016 - 2025)

Historic Receivables for Tandem Diabetes Care (TNDM) over the last 14 years, with Q3 2025 value amounting to $125.9 million.

  • Tandem Diabetes Care's Receivables rose 1749.45% to $125.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $125.9 million, marking a year-over-year increase of 1749.45%. This contributed to the annual value of $121.8 million for FY2024, which is 1542.42% up from last year.
  • Per Tandem Diabetes Care's latest filing, its Receivables stood at $125.9 million for Q3 2025, which was up 1749.45% from $128.4 million recorded in Q2 2025.
  • In the past 5 years, Tandem Diabetes Care's Receivables ranged from a high of $128.4 million in Q2 2025 and a low of $77.2 million during Q1 2021
  • Its 5-year average for Receivables is $104.8 million, with a median of $103.8 million in 2022.
  • Its Receivables has fluctuated over the past 5 years, first surged by 6651.86% in 2021, then crashed by 1106.95% in 2023.
  • Over the past 5 years, Tandem Diabetes Care's Receivables (Quarter) stood at $115.0 million in 2021, then dropped by 0.22% to $114.7 million in 2022, then decreased by 7.99% to $105.6 million in 2023, then rose by 15.42% to $121.8 million in 2024, then increased by 3.37% to $125.9 million in 2025.
  • Its last three reported values are $125.9 million in Q3 2025, $128.4 million for Q2 2025, and $126.6 million during Q1 2025.